Infigratinib Receives Breakthrough Therapy Designation in China for Gastric Cancer

China’s National Medical Products Administration has granted a breakthrough therapy designation to infigratinib for the treatment of patients with gastric cancer.

Related Keywords

China ,United States ,Yizhe Wang ,Bridgebio Pharma ,Helsinn Birex Pharmaceuticals ,United States Securities And Exchange Commission ,K Securities And Exchange Commission ,China National Medical Products Administration ,National Medical Products Administration ,Helsinn Healthcare ,States Securities And Exchange Commission ,Securities And Exchange ,Gastrointestinal Cancer ,Global Oncology ,News ,Febseltiq ,Nmpa ,Infigratinib ,Chinas National Medical Products Administration ,Gastric Cancer ,